Benzinga's Top #PreMarket Gainers

shares jumped 42.07% to $2.06 in pre-market trading after the company reported positive preliminary results from Phase 2a clinical trial of BIOD-531.

shares rose 40.78% to $7.25 in pre-market trading after the company provided clinical update for BIND-014.

shares jumped 14.55% to $10.55 in pre-market trading after the company received positive advice from the European Medicines Agency Regarding its Phase 3 program with Pyridorin.

shares surged 13.30% to $24.79 in pre-market trading after

, in cooperation with Neurocrine Biosciences, announces positive top-line results from Phase 3 study of investigational medicine elagolix.

shares gained 11.24% to $9.50 in the pre-market trading session following the report of additional positive data on important cardiac endpoint.